ntoutoume Nzoghe Pierre Constant

Mr. ntoutoume Nzoghe Pierre Constant

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2025 in International Journal of Risk & Safety in Medicine
Verified
Journal Article
Closed access
NCntoutoume Nzoghe Pierre Constant
ntoutoume Nzoghe Pierre Constant
RLRim Lakhmiri
Rim Lakhmiri
SCSophie Coniquet
Sophie Coniquet
LMLandry Missounga
Landry Missounga
SNSolange Ntsame
Solange Ntsame
SSSamira Serragui
Samira Serragui
Background: Stevens-Johnson syndrome (SJS), a rare and severe toxic epidermal necrolysis, is reported here for the first time at the University Hospital Center of Libreville (CHUL), suspected to be related to fluconazole administration. Objective: To inform clinicians about the risks associated with fluconazole in immunocompromised patients and the related healthcare expenses. Case presentation: The patient is a 39-year-old immunocompromised woman who received a single dose 400 mg of fluconazole. Two weeks later, she developed a rash affecting approximately 10 % of her body surface, confirmed as SJS. During clinical examinations, no signs of infection, such as fever, dizziness, or chills, were present, suggesting a drug-induced SJS reaction. Results: Causality assessment assigned an intrinsic score of I6 and extrinsic score of B2 according to the French method, and a probable temporal relationship was confirmed using the world Health Organization (WHO) method. The ALDEN scale identified fluconazole as the probable cause (score = 4). No additional risk factors were identified (SCORTEN = 0, predicted mortality: 3.2 %). Economically, the total direct medical cost of hospitalization amounted to 605,700 CFA francs, or 923.38 €. Conclusion: Immunocompromised HIV-positive patients treated with 400 mg of fluconazole are likely to develop SJS and incur costs.

16 January 2026 in Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
NCntoutoume Nzoghe Pierre Constant
ntoutoume Nzoghe Pierre Constant
RLRim Lakhmiri
Rim Lakhmiri
SCSophie Coniquet
Sophie Coniquet
SNSolange Ntsame
Solange Ntsame
IHIhsane Hmamouchi
Ihsane Hmamouchi
SSSamira Serragui
Samira Serragui
Background: According to the literature, adverse drug reactions (ADRs) account for 5–10% of hospital admissions and affect 25–30% of hospitalized patients, but no data are available for Gabon. Objectives: To estimate the incidence of ADRs among hospitalized patients at the Libreville University Hospital Center (CHUL) and to classify them according to their frequency, severity, mechanism and preventability, while proposing appropriate risk minimization strategies. Patients and Methods: A 14-month, single-center, prospective study included all patients experiencing ADRs, excluding those without ADRs or with intentional overdoses. ADRs were analyzed using the World Health Organization (WHO) causality assessment, the ATC classification, and Rawlins and Thompson criteria. Data were actively collected from patients and hospital records. Results: Among 4999 patients, 105 experienced 177 adverse events (incidence: 3.5%, 95% CI: 1.7–2.5%). Among the identified ADRs, 42% were serious. Nausea and vomiting were the most frequent ADRs, mainly caused by analgesics (nefopam, tramadol) and antibiotics (amoxicillin–clavulanic acid). The gastrointestinal and nervous systems were the most affected. According to the Rawlins and Thompson classification, 90% of ADRs were type A, 8% type B, and 2% type E (withdrawal syndrome). Overall, 90% of ADRs were preventable. Conclusions: This study highlights the importance of pharmacovigilance at CHUL, Gabon, and emphasizes the role of healthcare professionals in ADR reporting and risk minimization.

21 August 2026 in International Journal of Risk & Safety in Medicine
Verified
Journal Article
Closed access
NCntoutoume Nzoghe Pierre Constant
ntoutoume Nzoghe Pierre Constant
LMLandry Missounga
Landry Missounga
SCSophie Coniquet
Sophie Coniquet
SNSolange Ntsame
Solange Ntsame
RLRim Lakhmiri
Rim Lakhmiri
SSSamira Serragui
Samira Serragui
Background: Stevens–Johnson Syndrome (SJS) is a rare and severe drug-induced cutaneous reaction. However, clinical and economic data regarding its management remain poorly documented in Gabon. Therefore, this study aimed to describe the clinical characteristics, drug causality assessment, therapeutic management, and direct medical costs of four confirmed cases of SJS managed at the Libreville University Hospital Center (CHUL). Case report: Four confirmed cases of SJS related respectively to lidocaine, allopurinol, amoxicillin/clavulanic acid, and flucloxacillin were identified. Drug causality assessment, performed using the French causality assessment method, the World Health Organization (WHO) scale, and the ALDEN algorithm, indicated a probable causal relationship in all cases. SCORTEN scores ranged from 0 to 1, corresponding to an estimated mortality rate of 3.2%. Therapeutic management was based on symptomatic and supportive treatment, including Polaramine, Solumedrol, Dacryoserum, eosin solution, Fucithalmic, sodium bicarbonate, Fungizone, Dexeryl, ciprofloxacin, and Exomuc, with favorable clinical outcomes observed in all patients. The mean direct medical cost of management was estimated at 225,089 CFA francs (343.14 €), with a total cost of 860,355 CFA francs (1311.60 €) for the four cases. Conclusion: SJS remains a severe dermatological emergency associated with substantial management costs despite favorable clinical outcomes. These findings highlight the importance of strengthening pharmacovigilance activities and the prevention of serious adverse drug reactions.